OvaCheck - Correlogic Files for Chapter 11 Bankruptcy Protection | GenomeWeb Daily News | DxPGx | GenomeWeb

press release:- Correlogic Systems Obtains CE Mark for OvaCheck®

Correlogic Systems Obtains CE Mark for OvaCheck®

Saturday, 12 June 2010

"Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians...."

Correlogic Systems Obtains CE Mark for OvaCheck® | SYS-CON MEDIA

media: June 9th: "Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians...."

Arrayit Signs on Docro to Help Ovarian Cancer Diagnostic Gain FDA Clearance GenomeWeb

Vermillion's OVA1 became the first protein-based in vitro diagnostic multivariate index assay to receive FDA clearance [See PM 09/17/09] and earlier this month it and Quest Diagnostics began marketing OVA1.

In addition, Correlogic is in discussions with the FDA about its OvaCheck test,

and

Healthlinx, which launched its test called OvPlex in the UK in February, has said that it may launch the test in the US next year, if it receives regulatory approval.

This week, Arrayit said that OvaDx will be the market's first "comprehensive diagnostic for ovarian cancer" and will be targeted to all women over the age of 35.